Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Galectin Therapeutics announced that its management team will present and participate in one-on-one meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, highlighting their lead drug belapectin targeting serious liver diseases and ongoing cancer immunotherapy programs.